• 1
    Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 234857.
  • 2
    Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J Clin Invest 1991; 88: 34651.
  • 3
    Romagnani S. Human TH1 and TH2: doubt no more. Immunol Today 1991; 12: 2567.
  • 4
    Romagnani S. Lymphokine production by human T cells in disease states. Annu Rev Immunol 1994; 12: 22757.
  • 5
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Ann Rev Immunol 1989; 7: 14573.
  • 6
    Del Prete GF, De Carli M, Ricci M, Romagnani S. 1991b. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th1 clones is limited by their cytolytic capacity. J Exp Med 1991; 174: 80913.
  • 7
    Romagnani S. Understanding the role of Th1/Th2 cells in infection. Trends Microbiol 1996; 4: 14.
  • 8
    Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 78793.
  • 9
    Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 13846.
  • 10
    O'Garra A, Murphy KM. Role of cytokines in the development of Th1 and Th2 cells. Chem Immunol 1996; 63: 113.
  • 11
    Bucy RP, Karr L, Huang G-Q, Li J, Carter D, Honjo K, Lemons JA, Murphy KM, Weaver CT. 1995. Single cell analysis of cytokine gene coexpression during CD4+ T-cell phenotype development. Proc Natl Acad Sci USA 1995; 92: 75659.
  • 12
    Kelso A. Th1 and Th2 subsets: paradigm lost? Immunol Today 1995; 16: 3749.
  • 13
    Hu-Li J, Huang H, Ryan J, Paul WE. In differentiated CD4- T cells, interleukin 4 production is cytokine-autonomous, whereas interferon gamma production is cytokine-dependent. Proc Natl Acad Sci USA 1997; 94: 318994.
  • 14
    Annunziato F, Manetti R, Tomasevic L, Giudizi M-G, Biagiotti R, Giannò, Germano P, Mavilia C, Maggi E, Romagnani S. Expression and release of LAG-3-encoded protein by human CD4+ T cells are associated with IFN-γ production. FASEB J 1996; 10: 76776.
  • 15
    Nakamura T, Lee RK, Nam SY, et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-γ. J Immunol 1997; 158: 264853.
  • 16
    Annunziato F, Manetti R, Cosmi L, Galli G, Heusser CH, Romagnani S, Maggi E. Opposite regulatory effect of IL-4 and IFN-γ on CD30 and LAG-3 expression by activated human naive T cells. Eur J Immunol 1997; 27: 223943.
  • 17
    Jourdan P, Abbal C, Nora N, et al. IL-4 induces functional cell-surface expression of CXCR4 on human T cells. J Immunol 1998; 160: 41537.
  • 18
    Galli G, Annunziato F, Mavilia C, et al. Enhanced HIV expression during T helper 2-oriented responses due to the opposite regulatory effect of IL-4 and IFN-γ on Fusin/CXCR4. Eur J Immunol 1998; 28: 328090.
  • 19
    Szabo SJ, Glimcher LH, Ho I-C. Genes that regulate interleukin-4 expression in T cells. Curr Opin Immunol 1997; 9: 77681.
  • 20
    Assenmacher M, Scheffold A, Schmitz J, Segura Checa JA, Miltenyi S, Radbruch A. Specific expression of surface interferon-γ on interferon-γ-producing T cells from mouse and man. Eur J Immunol 1996; 26: 2637.
  • 21
    Xu D, Chan WL, Leung BP, et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 not Th2 cells. J Exp Med 1998; 188: 148592.
  • 22
    Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998; 8: 38390.
  • 23
    Pemis A, Gupta S, Gollob KJ, Garfein E, Coffman RL, Schindler C, Rothman P. Lack of interferon γ receptor β chain and the prevention of interferon γ signalling in Th1 cells. Science 1995; 269: 2457.
  • 24
    Kanegane H, Kasahara Y, Niida Y, Yachie A, Sugii S, Takatsu K, Taniguchi N, Miyawaki T. Expression of L-selectin (CD62L) discriminates Th1- and Th2-like cytokine-producing memory CD4+ T cells. Immunology 1996; 87: 18690.
  • 25
    Sallusto F, Mackay CR, Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper cells. Science 1997; 277: 20057.
  • 26
    Bonecchi R, Bianchi G, Bordignon Panina P, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of Th1 and Th2 cells. J Exp Med 1998; 187: 12934.
  • 27
    Zingoni A, Soto H, Hedrick JA, et al. The chemokine receptor CCR8 is preferentially expressed in Th2 but not Th1 cells. J Immunol 1998; 161: 54751.
  • 28
    Nagata K, Tanaka K, Ogawa K, et al. Selective expression of a novel surface molecule by human Th2 cells in vivo. J. Immunol 1999; 162: 127886.
  • 29
    Austrup F, Vestweber D, Borges E, Lohning M, Brauer R, Herz U, Renz H, Hallman R, Scheffold A, Radbruch A, Hamann A. P- and E-selectin mediate recruitment of T-helper-1 but not T-helper-2 cells into inflamed tissues. Nature 1997; 385: 813.
  • 30
    Borges E, Tietz W, Steegmaier M, Moll T, Hallmann R, Hamann A, Vestweber D. P-selectin glycoprotein ligand-1 (PSGL-1) on T helper 1 but not on T helper 2 cells binds to P-selectin and supports migration into inflamed skin. J Exp Med 1997; 185: 5738.
  • 31
    Loetscher P, Uguccioni MG, Bordoli L, Baggiolini M, Moser B, Chizzolini C, Dayer J-M. CCR5 is characteristic of Th1 lymphocytes. Nature 1998; 391: 34445.
  • 32
    Ebel F, Schmitt E, Peter-Katalinic J, Kniep B, Muhlradt PF. Gangliosides: differentiation markers for murine T helper lymphocyte subpopulations Th1 and Th2. Biochemistry 1992; 31: 121907.
  • 33
    Lohning M, Stroehmann A, Coyle AJ, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998; 95: 69305.
  • 34
    Xu D, Chan WL, Leung BP, et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J Exp Med 1998; 187: 78794.
  • 35
    Lohoff M, Prechtl S, Sommer F, et al. A multidrug-resistance protein (MRP)-like transmembrane pump is highly expressed by resting murine T helper (Th) 2, but not Th1 cells, and is induced to equal expression levels in Th1 and Th2 cells after antigenic stimulation in vivo. J Clin Invest 1998; 101: 70310.
  • 36
    Romagnani S. The Th1/Th2 paradigm in disease. Austin: Springer, Heidelberg/R. G. Landes Company, 1997.
  • 37
    Constant SL, Bottomly K. Induction of Th1 and Th2 CD4- T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15: 297322.
  • 38
    Lenschow DJ, Walunas TL, Bluestone JA, CD28/B7 system of T cell costimulation. Annu. Rev. Immunol 1996; 14: 23358.
  • 39
    Ohshima Y, Yang LP, Uchiyama T, et al. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors. Blood 1998; 92: 333845.
  • 40
    Tao X, Constant S, Jorritsma P, Bottomly K. Strength of TCR signal determines the costimulatory requirements for Th1 and Th2 CD4+ T cell differentiation. J Immunol 1997; 159: 595663.
  • 41
    Bendelac A, Hunziker R, Lantz O. Increased Interleukin 4 and Immunoglobulin E production in transgenic mice overexpressing NK1.1 T cells. J Exp Med 1996; 184: 128593.
  • 42
    Maggi E, Parronchi P, Manetti R, et al. Reciprocal regulatory role of IFN-γ and IL-4 on the in vitro development of human Th1 and Th2 cells. J Immunol 1992; 148: 21427.
  • 43
    Parronchi P, De Carli M, Manetti R, et al. IL-4 and IFN(s) (Alpha and Gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J Immunol 1992; 149: 297782.
  • 44
    Manetti R, Parronchi P, Giudizi M-G, Piccinni M-P, Maggi E, Trinchieri G, Romagnani S. Natural killer cell stimulatory factor (interleukin-12) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 1993; 177: 11991204.
  • 45
    Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Leisteria-induced macrophages. Science 1993; 260: 5479.
  • 46
    Armant M, Armitage R, Boiani N, Delespesse G, Sarfati M. Functional CD40 ligand expression on T lymphocytes in the absence of T cell receptor engagement: involvement in interleukin-2-induced interleukin-12 and interferon-gamma production. Eur J Immunol 1996; 26: 14304.
  • 47
    Rogge L, Barveris-Maino L, Biffi M, Passini N. Presky DH, Gubler U, Sinigaglia F. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997; 185: 82531.
  • 48
    Kalinski P, Schuitemaker JH, Hilkens CM, Kapsenberg ML. Prostaglandin E2 induces the final maturation of IL-12-deficient CD1a+CD83+ dendritic cells: the levels of IL-12 Are determined during the final dendritic cell maturation and are resistant to further modulation. J Immunol 1998; 161: 28049.
  • 49
    Pulendran B, Smith JL, Caspary G, Brasel K. Pettit D, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999; 96: 103641.
  • 50
    Bird JJ, Brown DR, Mullen AC, Moskowitz NH. Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL. Helper T cell differentiation is controlled by the cell cycle. Immunity 1998; 9: 22937.
  • 51
    Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380: 6302.
  • 52
    Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996; 380: 62730.
  • 53
    Dent AL, Hu-Li J, Paul WE, Staudt LM. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci USA 1998; 95: 138238.
  • 54
    Li-Weber M, Salgame P, Hu C, Krammer PH. Characterization of constitutive and inducible transcription factors binding to the P2 NF-AT site in the human interleukin-4 promoter. Gene 1997; 188: 25360.
  • 55
    Hodge MR, Chun HJ, Rengarajan J, Alt A. Lieberson R, Glimcher LH. NF-AT-Driven interleukin-4 transcription potentiated by NIP45. Science 1996; 274: 19035.
  • 56
    Ho CI, Hodge MR, Rooney JW, Glimcher LH. The protooncogene c-maf is responsible for tissue-specific expression of Interleukin-4. Cell 1996; 85: 97383.
  • 57
    Ko LJ, Yamamoto M, Leonard MW, George KM, Ting P, Engel JD. Murine and human T-lymphocyte GATA-3 factors mediate transcription through a cis-regulatory element within the human T cell receptor d gene enhancer. Mol Cell Biol 1991; 11: 277884.
  • 58
    Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 58796.
  • 59
    Thierfelder S, Mocikat R, Mysliwiet J, Lindhofer M, Kremmer E. Immunosuppression by Fc region-mismatched anti-T cell antibody treatment. Eur J Immunol 1995; 25: 22426.
  • 60
    Kaplan MH, Scindler U, Smiley ST, Grusby MJ. STAT 6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4: 31319.
  • 61
    Yang DD, Conze D, Whitmarsh AJ, Barrett T, Davis RJ, Rincon M, Flavell RA. Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2. Immunity 1998; 57585.
  • 62
    Nickerson P, Steurer W, Steiger J, Zheng X, Steele AW, Strom TB. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994; 6: 75764.
  • 63
    Wegmann TG, Lin H, Guilbert L, Mosmann RT. Bidirectional cytokine onteractions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol Today 1993; 14: 3536.
  • 64
    Piccinni M-P, Beloni L, Maggi E, Scarselli C, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 1998; 4: 10204.
  • 65
    Piccinni M-P, Giudizi M-G, Biagiotti R, et al. Progesterone favors the development of human T helper cells producing Th2-type cytokines and promotes both IL-4 production and membrane CD30 expression in established Th1 cell clones. J Immunol 1995; 155: 12833.
  • 66
    Schandené L, Ferster A, Mascart-Lemone F, et al. T helper type 2-like cells and therapeutic effects of interferon-γ in combined immunodeficiency with hypereosinophilia (Ommen's syndrome). Eur J Immunol 1993; 23: 5660.
  • 67
    Chilosi M, Facchetti F, Notarangelo LD, Romagnani S, Del Prete G-F, Almerigogna F, De Carli M, Pizzolo G. CD30 cell expression and abnormal soluble CD30 serum accumulation in Omenn's syndrome. Evidence for a Th2-mediated condition. Eur J Immunol 1996; 26: 32934.
  • 68
    Clerici M, Shearer GM. A TH1 — TH2 switch is a critical step in the etiology of HIV infection. Immunol Today 1993; 14: 10711.
  • 69
    Maggi E, Mazzetti M, Ravina A, et al. Ability of HIV-1 to promote a Th1 to Th0 shift and to replicate preferentially in Th2 and Th0 cells. Science 1994; 265: 2448.
  • 70
    Romagnani S. Regulation of Th2 development in allergy. Curr Opin Immunol 1994; 6: 83846.
  • 71
    Romagnani S. Atopic allergy and other hypersensitivities editorial overview: technological advances and new insights into pathogenesis prelude novel therapeutic strategies. Curr Opin Immunol 1995; 7: 74550.
  • 72
    Romagnani S. The Th2 hypothesis in allergy. “Eppur si muove!” ACI Intern 1998; 10: 15864.
  • 73
    Wierenga EA, Snoek M, de Groot C, Chretien I, Bos JD, Jansen HM, Kapsenberg ML. Evidence for compartmentalization of functional subsets of CD4+ T lymphocytes in atopic patients. J Immunol 1990; 144: 46516.
  • 74
    Parronchi P, Macchia D, Piccinni M-P, et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 1991; 88: 453842.
  • 75
    Hamid Q, Azzawi M, Ying S, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87: 15416.
  • 76
    Robinson DS, Hamid Q, Ying S, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. New Engl J Med 1992; 326: 295304.
  • 77
    Del Prete G-F, De Carli M, D'Elios MM, Maestrelli P, Ricci M, Fabbri L, Romagnani S. Allergen exposure induces the activation of allergen-specific Th2 cells in the airway mucosa of patients with allergic respiratory disorders. Eur J Immunol 1993; 23: 14459.
  • 78
    Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med 1993; 178: 212330.
  • 79
    Varney VA, Hamid Q, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest 1993; 92: 64451.
  • 80
    Kopf M, Le Gros G, Bachmann M, Lamers MC, Bluethman H, Kohler G. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362: 2458.
  • 81
    Mackenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie ANJ. Simulataneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1998; 189: 156572.
  • 82
    Wang J, Palmer K, Lotvall J, et al. Circulating, but not local lung, IL-5 is required for the development of antigen-induced airways eosinophilia. J Clin Invest 1998; 102: 113241.
  • 83
    Shirikawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorders. Science 1997; 275: 779.
  • 84
    Matricardi PM, Rosmini F, Ferrigno L, et al. Cross sectional retrospective study of prevalence of atopy among Italian military students with antibodies against hepatitis A virus. Br Med J 1997; 314: 9991003.
  • 85
    Mavilia C, Scaletti C, Romagnani P, et al. Type 2 helper T (Th2) cell predominance and high CD30 expression in systemic sclerosis. Amer J Pathol 1997; 6: 17518.
  • 86
    Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T helper (Th1)-predominance and IL-12 expression in the gut of patients with Crohn's disease. Amer J Pathol 1997; 150: 82332.
  • 87
    Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, Pallone F. Interleukin 12 is expressed and actively releases by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997; 112: 116978.
  • 88
    Pizarro TT, Michie MH, Bentz M, et al. IL-18, a novel immuno-regulatory cytokine, is up-regulated in Crohn's disease: expression and localization in intestinal mucosai cells. J Immunol 1999; 162: 682935.
  • 89
    Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol 1996; 156: 495260.
  • 90
    Scheel D, Richter E, Toellner K-M, et al. Correlation of CD26 expression with Th1-like reactions in granulomatous diseases. In: Leukocyte Typing V “White Cell Differentiation Antigens.” SchlossmannSF. BoumsellSFL, GilksW, ET AL. (EDS.) Oxford: Oxford University Press, 1995; p. 1111
  • 91
    Del Prete G-F, De Carli M, Almerigogna F, Daniel KC, Zancuoghi MM, Vinante E, Pizzolo G, Romagnani S. Preferential Expression of CD30 by Human CD4+ T Cells Producing Th2-type Cytokines. FASEB J 1995; 9: 816.
  • 92
    Del Prete GF, Tiri A, De Carli M, et al. High potential to tumor necrosis factor a (TNF-a) production of thyroid infiltrating T lymphocytes in Hashimoto's thyroiditis: a peculiar feature of destructive thyroid autoimmunity. Autoimmunity 1989; 4: 26776.
  • 93
    De Carli M, D'Elios MM, Mariotti S, Marcocci C, Pinchera A, Ricci M, Romagnani S, Del Prete G-F. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophtalmopathy. J Clin Endocrinol Metab 1993; 77: 11204.
  • 94
    Brod S, Benjamin D, Hafler DA. 1991. Restricted T cell expression of IL2/IFN-γ mRNA in human inflammatory disease. J Immunol 1991; 147: 81015.
  • 95
    Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991; 87: 94954.
  • 96
    Kallan AA, Duinkerken G, de Jong R, et al. Th1-like cytokine production profile and individual specific alterations in TCRbV-gene usage of T cells from newly diagnosed type 1 diabetes patients after stimulation with β-cell antigens. J Autoimmun 1997; 10: 58998.
  • 97
    Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokines patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994; 91: 85626.
  • 98
    Yssel H, Shanafelt MC, Soderberg C, Schneider PV, Anzola J, Peltz G. Borrelia burgdorferi activates a T helper type 1-like T cell subset in Lyme arthritis. J Exp Med 1991; 174: 593601.
  • 99
    Schlaak J, Hermann E, Ringhoffer M, Probst P, Gallati H, Meyer zum Buschenfelde KH, Fleischer B. Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. Eur. J. Immunol 1992; 22: 27716.
  • 100
    Benvenuto RA, Bachloni A, Cinti P, Sallusto F, Franco F, Molajoni ER, Barnaba V, Balsano F, Cortesini R. Enhanced production of interferon-γ by T lymphocytes cloned from rejected kidney grafts. Transplantation 1991; 51: 88792.
  • 101
    D'Elios MM, Manghetti M, De Carli M, et al. Th1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer. J Immunol 1997; 158: 9627.
  • 102
    Maggi E, Biswas P, Del Prete G-F, et al. Accumulation of Th2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 1991; 146: 116974.
  • 103
    Wallace WA, Ramage EA, Lamb D, Howie SE. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA). Clin Exp Immunol 1995; 101: 43641.
  • 104
    Sigusch B, Klinger G, Glockmann E, Simon HU. Early-onset and adult periodontitis associated with abnormal cytokine production by activated T lymphocytes. J Periodontol 1998; 69: 10981104.
  • 105
    Roussel E, Gingras MC, Grimm EA, Bruner JM, Moser RP. Predominance of a type 2 intratumoral immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin. Exp. Immunol 1996; 105: 34452.
  • 106
    Inagawa H, Nishizawa T, Honda T, Nakamoto T, Takagi K, Soma G. Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 1998; 18: 395764.
  • 107
    Skeiky JAW, Gauderian JA, Benson DR, et al. A recombinant Leishmania antigen that stimulates human peripheral blood mononuclear cells to express a Th1-type cytokine profile and to produce interleukin-12. J Exp Med 1995; 181: 152737.
  • 108
    Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlink JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect Immun 1995; 63: 42617.
  • 109
    Wang ZE, Zheng S, Corry DB, Dalton DK, Seder RA, Reiner SL, Locksley RM. Interferon γ-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major. Proc Natl Acad Sci USA 1994; 91: 129326.
  • 110
    Mountford AP, Anderson S, Wilson RA. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J Immunol 1996; 156: 473945.
  • 111
    Huygen K, Content J, Denis O, et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine. Nat Med 1996; 8: 8938.
  • 112
    Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. 1997. DNA vaccines. Annu Rev Immunol 1997; 15: 61748.
  • 113
    Moldoveanu Z, Love-Homan L, Huang WQ, Krieg AM. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 1998; 11–12: 121624.
  • 114
    McCluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998; 161: 44636.
  • 115
    Lord CJM, Lamb JR. TH2 cells in allergic inflammation: a target of immunotherapy. Clin Exp Allergy 1996; 26: 75665.
  • 116
    Coyle AJ, Tsuyuki S, Bertrand C, Huang S, Aguet M, Alkan SS, Anderson GP. Mice lacking the IFN-gamma receptor have an impaired ability to resolve a lung eosinophilic inflammatory response associated with a prolonged capacity of T cells to exhibit a Th2 cytokine profile. J Immunol 1996; 156: 26805.
  • 117
    Hofstra CL, Van Ark I, Hofman G, Kool M, Nijkamp FP, Van Oosterhout AJ. Prevention of Th2-like cell responses by coadministration of IL-12 and IL-18 is associated with inhibition of antigen-induced airway hyperresponsiveness, eosinophilia, and serum IgE levels. J Immunol 1998; 161: 505460.
  • 118
    Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guérin suppresses allergen-induced airway eosinophilia. J Exp Med 1998; 187: 5619.
  • 119
    Hsu CH, Chua KY, Tao MH, Huang SK, Hsieh KH. Inhibition of specific IgE response in vivo by allergen-gene transfer. Int Immunol 1996; 8: 140511.
  • 120
    Raz E, Tighe E, Sato Y, et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996; 93: 51415.
  • 121
    Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997; 186: 162331.
  • 122
    Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW. Raz E. Immuno-stimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998; 161: 705462.
  • 123
    Grunewald SM, Werthmann A, Schnarr B, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998; 160: 40049.
  • 124
    Kung TT, Stelts DM, Zurcher JA, et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and theraputic effect of an anti-IL-5 antibody. Am J Respir Cell Mol Biol 1995; 13: 3605.
  • 125
    Mori A, Suko M, Kaminuma P, et al. Enhanced Production and Gene Expression of IL-5 in Bronchial Asthma. Possible Management of Atopic Diseases with IL-5 Specific Gene Transcription Inhibitor. In: Molecular Biology of Allergens and the Atopic Immune Response. SehonA, KraftD, eds. New York: Pienum Press, 1996.
  • 126
    Jardieu P, Anti-IgE therapy. Curr. Opin. Immunol 1995; 7: 77982.
  • 127
    Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99: 87987.
  • 128
    Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Antigen-specific TGF-betal secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci 1996; 778: 2517.
  • 129
    Sieper J, Kary S, Sorensen H, et al. Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996; 39: 4151.
  • 130
    Rocken M, Racke M, Shevach E. Interleukin 4-induced immune deviation as antigen-specific therapy for inflammatory auotimmune disease. Immunol Today 1996; 17: 22531.
  • 131
    van Roon JAG, van Roy JLAM, Gmelig-Meyling FHJ, Lafeber FPJG, Bijlsma WJ. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 82935.